As of November 7, 2026, Phio Pharmaceuticals Corp. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 21, 2026, naming 1 appointment. The latest filing names R. Todd Plott, appointed (Form 8-K, July 21, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Phio Pharmaceuticals Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Phio Pharmaceuticals Corp. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-21. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Phio Pharmaceuticals Corp. files it.
Also on the record for Phio Pharmaceuticals Corp.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 17, 2026 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 9.9% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | 9.1% of the class | 5%+ stakes | Source |
| December 11, 2025 | Stake report, Schedule 13G/A, by Orca Capital AG | 4.9% of the class | 5%+ stakes | Source |
| November 24, 2025 | Stake report, Schedule 13G/A, by Orca Capital AG | 6.5% of the class | 5%+ stakes | Source |
| November 12, 2025 | Form D, private offering | $1.42M sold | Form D page | Source |
| November 12, 2025 | Stake report, Schedule 13G/A, by Orca Capital AG | 4.9% of the class | 5%+ stakes | Source |
| November 10, 2025 | Stake report, Schedule 13G, by CVI Investments, Inc. | 9.9% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G/A, by Mitchell P. Kopin | 7% of the class | 5%+ stakes | Source |
| November 6, 2025 | Stake report, Schedule 13G/A, by Orca Capital AG | 9.8% of the class | 5%+ stakes | Source |
| August 7, 2025 | Stake report, Schedule 13G/A, by Orca Capital AG | 4.9% of the class | 5%+ stakes | Source |
| August 4, 2025 | Form D, private offering | $232K sold | Form D page | Source |
| January 28, 2025 | Form D, private offering | $208K sold | Form D page | Source |
Selling to them or working with them? See who runs Phio Pharmaceuticals Corp. now and the warning signs.
Free to see. No signup.
Keep reading
More on Phio Pharmaceuticals Corp. and the records around it.
Phio Pharmaceuticals Corp. elsewhere on the record
- 5%+ stake filings Feb 2026
- Form D filing Nov 2025
- Form D filing Aug 2025
- Who owns it
Companies that share a holder
- Orca Capital AG also filed stake reports on 19 other companies: DarkIris Inc. (Oct 2026), Neo-Concept International Group Holdings Limited (Oct 2026), NFT Limited (Sep 2026)
- CVI Investments, Inc. also filed stake reports on 48 other companies: Pine Tree Acquisition Corp. (Oct 2026), Sunshine Biopharma Inc. (Oct 2026), Outlook Therapeutics, Inc. (Aug 2026)
- Mitchell P. Kopin also filed stake reports on 55 other companies: SCWorx Corp. (Sep 2026), NFT Limited (Aug 2026), Silexion Therapeutics Corp (Aug 2026)
Watch Phio Pharmaceuticals Corp.
Get an email when Phio Pharmaceuticals Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Phio Pharmaceuticals Corp.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Phio Pharmaceuticals Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Phio Pharmaceuticals Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 16 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-21 | In | 2026-07-20 | 8-K, 2026-07-21 |
New leaders reset buying decisions — get the Full Report on Phio Pharmaceuticals Corp.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Phio Pharmaceuticals Corp., with the record behind each one.
Find candidates like senior executive at Phio Pharmaceuticals Corp.Every change, in the filing's words
Appointed: R. Todd Plott, effective 2026-07-20
Effective as of July 20, 2026, the Board of Directors (the "Board") of Phio Pharmaceuticals Corp. (the "Company") increased the size of the Board to six members and appointed R. Todd Plott, M.D. to serve on the Board until the 2026 annual meeting of stockholders.
- Dr. Plott was also appointed to serve as a member of the Board's Governance Committee.
- Dr. Plott is a board-certified dermatologist, accomplished researcher, inventor, and former FDA advisory committee member with more than 30 years of experience in dermatologic care and innovation.
- In connection with Dr. R. Todd Plott, M.D.'s appointment to the Board, Dr. R. Todd Plott, M.D. will enter into the Company's standard form of indemnification agreement.
- Pursuant to the terms of the indemnification agreement, the Company may be required, among other things, to indemnify Dr. R. Todd Plott, M.D. for some expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service on the Board.
- In addition, Dr. R. Todd Plott, M.D. will receive standard compensation and equity awards available to non-employee directors of the Company.
- The Company's non-employee director compensation program is described in the "Director Compensation" section of the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 5, 2026.
Tools for this story
Each opens in a new tab, filled in for Phio Pharmaceuticals Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.